Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 11 » default
Pharmacogenomics and Personalized Medicine
ISSN: 1178-7066
- View all (573)
- Volume 16, 2023 (49)
- Volume 15, 2022 (82)
- Volume 14, 2021 (155)
- Volume 13, 2020 (72)
- Volume 12, 2019 (34)
- Volume 11, 2018 (24)
- Volume 10, 2017 (31)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Archive: Volume 11, 2018
Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders
Menke A
Pharmacogenomics and Personalized Medicine 2018, 11:211-222
Published Date: 19 November 2018
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study
Baghdadi LR, Woodman RJ, Shanahan EM, Wiese MD, Mangoni AA
Pharmacogenomics and Personalized Medicine 2018, 11:205-210
Published Date: 12 November 2018
Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients
Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevska-Angelovska N, Panovski M, Grozdanovska B, Mitreski N, Dimovski A
Pharmacogenomics and Personalized Medicine 2018, 11:193-203
Published Date: 1 November 2018
CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort
Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, van Schaik RHN
Pharmacogenomics and Personalized Medicine 2018, 11:179-191
Published Date: 24 October 2018
Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients
Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Calderón-Ospina CA, Peña N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ
Pharmacogenomics and Personalized Medicine 2018, 11:169-178
Published Date: 16 October 2018
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]
Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T
Pharmacogenomics and Personalized Medicine 2018, 11:167-168
Published Date: 26 September 2018
Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension
Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E
Pharmacogenomics and Personalized Medicine 2018, 11:157-165
Published Date: 20 September 2018
ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
Uruga H, Mino-Kenudson M
Pharmacogenomics and Personalized Medicine 2018, 11:147-155
Published Date: 17 September 2018
Qualitative user evaluation of a revised pharmacogenetic educational toolkit
Mills R, Haga SB
Pharmacogenomics and Personalized Medicine 2018, 11:139-146
Published Date: 4 September 2018
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty
Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T
Pharmacogenomics and Personalized Medicine 2018, 11:127-137
Published Date: 25 July 2018
The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA
Pharmacogenomics and Personalized Medicine 2018, 11:121-126
Published Date: 20 July 2018
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2018, 11:113-119
Published Date: 29 June 2018
CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA
Pharmacogenomics and Personalized Medicine 2018, 11:107-112
Published Date: 18 June 2018
Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population
Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J
Pharmacogenomics and Personalized Medicine 2018, 11:95-106
Published Date: 8 June 2018
Emerging biomarkers in the diagnosis of prostate cancer
Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L
Pharmacogenomics and Personalized Medicine 2018, 11:83-94
Published Date: 16 May 2018
Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation
Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP
Pharmacogenomics and Personalized Medicine 2018, 11:71-82
Published Date: 23 April 2018
Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer
Szucs TD, Szillat KP, Blozik E
Pharmacogenomics and Personalized Medicine 2018, 11:67-69
Published Date: 23 April 2018
H3Africa: current perspectives
Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ
Pharmacogenomics and Personalized Medicine 2018, 11:59-66
Published Date: 10 April 2018
CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment
Silvado CE, Terra VC, Twardowschy CA
Pharmacogenomics and Personalized Medicine 2018, 11:51-58
Published Date: 29 March 2018
Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke
Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO
Pharmacogenomics and Personalized Medicine 2018, 11:43-49
Published Date: 22 March 2018
The utility of pharmacogenetic testing to support the treatment of bipolar disorder
Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C
Pharmacogenomics and Personalized Medicine 2018, 11:35-42
Published Date: 16 March 2018
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
Chen L, Prasad GV
Pharmacogenomics and Personalized Medicine 2018, 11:23-33
Published Date: 7 March 2018
Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study
Plöthner M, Schmidt K, Schips C, Damm K
Pharmacogenomics and Personalized Medicine 2018, 11:7-21
Published Date: 14 February 2018
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction
Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2018, 11:1-5
Published Date: 28 December 2017